A melanoma vaccine made from your own tumour cut recurrence by 42%
The full story behind my Short: In the phase 3 INTerpath-001 trial (1,137 patients), a personalised mRNA vaccine plus Keytruda cut the risk of melanoma recurrence or death by 42% vs Keytruda alone (82% vs 70% at 2 years). Survival data are not mature yet.
Watch the Short
It's too early to say whether this vaccine helps people live longer, and it is not approved. This page is not medical advice. If you have melanoma, talk to your cancer team.
The short version
Moderna and Merck's personalised mRNA cancer vaccine, intismeran autogene (also known as V940 / mRNA-4157), is made for each patient from their own tumour. In a large phase 3 trial, adding it to the immunotherapy Keytruda (pembrolizumab) after surgery lowered the chance of melanoma coming back, or death, compared with Keytruda alone. The results were presented at the ESMO 2026 congress in Madrid [1][2].
What they found
Each patient's tumour is sequenced, and the vaccine encodes up to 34 neoantigens (abnormal proteins found in that cancer) in mRNA, training the immune system to recognise them [1][2].
INTerpath-001 was a randomised, double-blind, placebo-controlled phase 3 trial in 1,137 people whose high-risk (stage IIB to IV) cutaneous melanoma had been completely removed by surgery. Everyone received Keytruda; two thirds also got the vaccine and one third got a placebo [1][2].
At a median follow-up of 24.6 months, the risk of recurrence or death was 42% lower with the combination (hazard ratio 0.58, 95% CI 0.45–0.75). At 2 years, 82.2% of people on the combination were alive without recurrence, versus 70.0% on Keytruda alone [1][2][3]. Distant metastasis-free survival also improved (88.5% vs 80.2% at 2 years) [3].
The most common side effects with the vaccine were fever (52.2% vs 8.2% with placebo) and injection-site pain (51.0% vs 9.5%), mostly mild. Serious (grade 3 or higher) side effects were 23.6% vs 20.3% [3].
Limits and caveats
- Survival unknown. Overall survival data are immature and not statistically significant so far (HR 0.77, 95% CI 0.45–1.31), so it's too early to say whether the vaccine helps people live longer [3].
- Interim analysis. These are interim results presented at a congress; the full paper has not yet been published.
- Benefit appeared later. There was no difference in the first 6 months (HR 0.99); the separation came after that (HR 0.42) [3].
- Not approved. The vaccine isn't approved anywhere yet; the companies say they are talking to regulators.
- Treatment, not prevention. It's given to people who already have melanoma. It is not a vaccine to prevent cancer.
Why it matters
Melanoma that has been removed can come back, and people with high-risk disease often get immunotherapy after surgery to reduce that risk. A phase 3 trial showing that a vaccine tailored to each patient's tumour adds to that benefit is a big step for personalised cancer vaccines. Whether it also helps people live longer still has to be shown.
Full narration (transcript)
A vaccine made from a patient's own tumour cut melanoma recurrence or death by 42 percent. Moderna and Merck's phase three trial followed over 1,100 people after melanoma surgery. All got Keytruda; two thirds also got the vaccine. At two years, 82 percent were alive without recurrence, versus 70 percent without it. Survival data aren't mature, it's not approved, and this isn't medical advice. Would you want a vaccine built from your own tumour? Follow the link to the main website for much deeper information.
Sources
- [1] Medical Xpress (October 2026). Personalized cancer vaccine plus immunotherapy cuts melanoma recurrence. https://medicalxpress.com/news/2026-10-personalized-cancer-vaccine-immunotherapy-melanoma.html
- [2] Merck (2026). Merck and Moderna will present results from landmark phase 3 INTerpath-001 trial at ESMO 2026 Presidential Symposium. https://www.merck.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium/
- [3] CancerNetwork (2026). INTerpath-001 data detail survival, subgroup, and safety findings in melanoma. https://www.cancernetwork.com/view/interpath-001-data-detail-survival-subgroup-and-safety-findings-in-melanoma
Credits
Images via Wikimedia Commons (illustrative unless stated): Melanoma (5).jpg (Unknown photographer, Public domain); Killer T cells surround a cancer cell.png (The National Institutes of Health, Public domain); COVID-19 Vaccination (20210318-OC-LSC-0001).jpg (USDAgov, Public domain). On-screen graphics: own.
AI voice note: the narration in the Short is an AI clone of my own voice (Chatterbox TTS by Resemble AI, MIT licence), used with my consent. I wrote the script and checked the figures against the sources above.
This page is general information, not medical advice. If you have melanoma, talk to your cancer team.